James Patrick Andrus
Physician at Bradbury Ln, Redwood City, CA

6566401, May 20, 2003

Apr 11, 2001

09/833228

Leonard A. Herzenberg - Stanford CA
Leonore A. Herzenberg - Stanford CA
Stephen C. De Rosa - Bethesda MD
James Andrus - Redwood City CA

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

A61K 31195

514562

The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent. The invention also provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent whose side effects are made worse by increased oxidative stress or treatment related decreases in subject cysteine/glutathione levels or are otherwise relieved by administration of NAC.

7723389, May 25, 2010

Nov 4, 2002

10/287175

Leonard A. Herzenberg - Stanford CA, US
Leonore A. Herzenberg - Stanford CA, US
Stephen C. De Rosa - Seattle WA, US
James Andrus - Redwood City CA, US

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

A61K 31/195, A61K 31/65, A61K 31/63, A61K 31/60, A61K 31/43, A61K 31/545

514562, 514563, 514561, 514151, 514153, 514154, 514155, 514156, 514157, 514158, 514159, 514192, 514193, 514194, 514195, 514196, 514197, 514198, 514199, 514200, 514201, 514202, 514203, 514204, 514205, 514206, 514207, 514208, 514209

The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent. The invention also provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent whose side effects are made worse by increased oxidative stress or treatment related decreases in subject cysteine/glutathione levels or are otherwise relieved by administration of NAC.

2005007, Mar 31, 2005

Aug 19, 2004

10/921679

James Andrus - Redwood City CA, US
Leonard Herzenberg - Stanford CA, US
Leonore Herzenberg - Stanford CA, US
David Aiello - Woodbridge, CA
John Mantovani - Menlo Park CA, US

A61K031/198

514562000

Life-threatening hepatotoxicity in the setting of acetaminophen overdose is due to depletion of glutathione (GSH), a vital cysteine-containing tripeptide that protects cells and organs against oxidant injury. Rapid administration of N-acetylcysteine (NAC), which provides the cysteine necessary to replenish the depleted GSH, is the standard of care for preventing injury in acetaminophen overdose. Beneficial effects of NAC treatment have also been demonstrated in respiratory, cardiovascular, endocrine and infectious and other diseases. In fact, over fifty randomized placebo-controlled trials conducted in diverse clinical settings document positive responses to NAC treatment. The present invention relates to cysteine/glutathione (GSH) deficiency as a previously unrecognized clinical entity that can complicate the course of commonly encountered diseases and methods of treatment of this generalized deficiency involving administering N-acetylcysteine (NAC) or a pharmaceutically acceptable salt or derivative to a subject in need thereof and monitoring the subjects appropriate glutathione blood levels as needed.

2011001, Jan 20, 2011

Jul 15, 2010

12/837341

Leonore A. Herzenberg - Stanford CA, US
James Andrus - Redwood City CA, US

A61K 31/198, A61K 9/28, A61P 29/00

424474, 514562

The present invention relates to compositions for improving the efficacy of acetaminophen comprising a unit dose of acetaminophen and a therapeutic efficacy-enhancing amount of N-acetylcysteine, such that acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cysteine ranging from about 1:15 to about 1:0.000977, and use of such compositions for analgesic and antipyretic applications.